EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...
AstraZeneca breast cancer therapy wins recommendation for EU approval
(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...
precisionmedicineonline20h
CHMP Recommends Approval of AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
Le Lézard1d
Varda Space Industries Makes History with the First Successful Commercial Space Reentry in Australia
Varda Space Industries, Inc., a microgravity-enabled life sciences company, today announced the successful landing of its second reentry capsule, W-2, and the completion of the company's second ...
AIM announces principal investigator for Ampligen, FluMist clinical study
AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...
EuropaWire21h
Breakthrough Discovery Targets Undruggable Cancer Protein, Opening Doors for New Treatments
Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4 ...